Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Applied Molecular Evolut. (NasdaqNM:AMEV)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug  7Earnings Announcement
Location
3520 Dunhill Street
San Diego, CA 92121
Phone: (858) 597-4990
Fax: (858) 597-4950
Employees (last reported count): 47
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 64%
·Over the last 6 months:
 · 2 insider buys; 1,000  shares
 · 3 insider sells; 75.0K shares
  (0.5% of insider shares)
·Institutional: 38% (105% of float)
(63 institutions)
·Net Inst. Buying: 1.32M shares (+12.88%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Applied Molecular Evolution Inc. is engaged in the application of directed evolution to the development of biotherapeutics. Directed evolution is a process for optimizing genes and proteins for specific commercial purposes. The Company uses its proprietary AMEsystem technology to rapidly create protein improvements, which would be too inefficient and expensive to achieve through conventional methods. The Company plans to use its directed evolution technology to develop improved versions of marketed, FDA-approved biopharmaceuticals, as well as novel human biotherapeutics. The components of the AMEsystem, DirectAME, ExpressAME and SelectAME, are designed to be precise and efficient methods for conducting the three fundamental steps of directed evolution and address the limitations of alternative directed-evolution approaches.
More from Market Guide: Expanded Business Description

Financial Summary
Applied Molecular Evolution utilizes directed evolution technology to develop improved versions of currently marketed, FDA-approved drugs as well as novel human therapeutics. For the six months ended 6/30/01, revenues rose 34% to $1.6 million. Net loss applicable to Common fell 60% to $6.7 million. Revenues reflect increased corporate NIH grants, collaboration and Kauffman patent licencing. Net loss also reflects the absence of series F preferred dividends.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Costa Sevastopoulos, Ph.D., 57
Chairman
--  
William Huse, M.D., Ph.D., 46
Pres, CEO, Director
$335K
Lawrence Bloch, M.D., 35
CFO, VP-Bus. Devel., Sec.
182K
Jeffry Watkins, Ph.D., 39
VP of Research
176K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:AMEVAs of 31-Aug-2001
Price and Volume
52-Week Low
on 21-Mar-2001
$5.75 
Recent Price$9.97 
52-Week High
on 29-Sep-2000
$40.25 
Daily Volume (3-month avg)93.5K
Daily Volume (10-day avg)36.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-69.1%
52-Week Change
relative to S&P500
-58.5%
Share-Related Items
Market Capitalization$235.3M
Shares Outstanding23.6M
Float8.50M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$4.01 
Earnings (ttm)-$0.69 
Earnings (mrq)-$0.16 
Sales (ttm)$0.15 
Cash (mrq)$3.83 
Valuation Ratios
Price/Book (mrq)2.49 
Price/EarningsN/A 
Price/Sales (ttm)65.02 
Income Statements
Sales (ttm)$3.10M
EBITDA (ttm)-$8.85M
Income available to common (ttm)-$13.8M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-17.02%
Return on Equity (ttm)-17.57%
Financial Strength
Current Ratio (mrq)52.38 
Debt/Equity (mrq)0 
Total Cash (mrq)$85.9M
Short Interest
As of 8-Aug-2001
Shares Short374.0K
Percent of Float4.4%
Shares Short
(Prior Month)
458.0K
Short Ratio6.03 
Daily Volume62.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.